The thesis

COAG is a clinical-stage biotechnology firm transforming blood coagulation disorder treatments. The company has a conviction tier of 34/100, indicating moderate skepticism. With a P/E ratio of -19.3x, COAG's valuation raises concerns. The analyst consensus rating of BUY contrasts with the company's low conviction score.

Why now

The current macro context, with the US-China squeeze and Middle East war, creates uncertainty for biotechnology firms like COAG. The company's low conviction score and negative P/E ratio make it a compelling watchlist candidate, particularly given the analyst consensus rating of BUY.

What to watch

Investors should monitor COAG's upcoming clinical trial results and updates on its pipeline development over the next 1-3 quarters. The company's ability to achieve positive trial outcomes and demonstrate progress in its mission to transform blood coagulation disorder treatments will be crucial in confirming or denying the thesis.

Key risks

COAG faces valuation risk due to its negative P/E ratio, which may indicate overvaluation. Execution risk is also a concern, as the company's clinical-stage status makes it vulnerable to trial failures. Additionally, macro risk from the US-China squeeze and Middle East war may impact the biotechnology sector as a whole.